This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

NCT03343678 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company strategic decision

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: Venetoclax
DRUG: BI 836826

Sponsor

Boehringer Ingelheim